6-chloro-3-methyl-1-(tetrahydropyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid | 1429171-54-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 6-chloro-3-methyl-1-(tetrahydropyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid
• 英文别名: 6-Chloro-3-methyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid；6-chloro-3-methyl-1-(oxan-2-yl)pyrazolo[3,4-b]pyridine-4-carboxylic acid
• CAS: 1429171-54-9
• 化学式: C₁₃H₁₄ClN₃O₃
• 分子量: 295.725
• InChiKey: XURQQWRLPFCDCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  77.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-3-methyl-1-(tetrahydropyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 在 四(三苯基膦)钯 、 2-bromo-1-ethylpyridin-1-ium tetrafluoroborate 、 N,N-二异丙基乙胺 、 cesium fluoride 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 1.5h， 生成 3-methyl-4-{3-methyl-1-(tetrahydropyran-2-yl)-6-[4-(tetrahydropyran-2-yloxy)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carbonyl}-3-phenylpiperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

  摘要：

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。

  公开号：

  US20130085128A1
• 作为产物：
  描述：

  6-羟基-3-甲基-1H-吡唑并[3,4-b]吡啶-4-羧酸乙酯 在 对甲苯磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 异丙醇 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 8.0h， 生成 6-chloro-3-methyl-1-(tetrahydropyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid
  参考文献：
  名称：

  6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

  摘要：

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。

  公开号：

  US20130085128A1

文献信息

• [EN] 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS AMIDES D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIQUE EN TANT QU'INHIBITEURS DE KINASE
  申请人：SANOFI SA

  公开号：WO2013037390A1

  公开（公告）日：2013-03-21

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及具有以下式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，可用于治疗与糖尿病及糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，该发明还涉及将式I的化合物用作药物中的活性成分，以及包含它们的药物组合物。
• 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130085128A1

  公开（公告）日：2013-04-04

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。式I的化合物是激酶抑制剂，适用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，本发明还涉及式I的化合物的用途，特别是作为药物中的活性成分以及包含它们的药物组合物。
• 6-(4-hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：Sanofi

  公开号：US08686150B2

  公开（公告）日：2014-04-01

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4、R5、R6和R7如下所示。公式I的化合物是激酶抑制剂，适用于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变。本发明还涉及公式I的化合物的用途，特别是作为药物活性成分以及包含它们的制药组合物。
• 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：EP2567959A1

  公开（公告）日：2013-03-13

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula are kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式中的吡唑并[3,4-b]吡啶化合物、 其中 R1、R2、R3、R4 和 R5 的定义如下所示。式中化合物是激酶 C (PKC) 抑制剂，可用于治疗与糖尿病和糖尿病并发症有关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变。本发明还涉及式化合物的用途，特别是作为药物的活性成分，以及包含它们的药物组合物。
• 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  申请人：SANOFI

  公开号：EP2760862A1

  公开（公告）日：2014-08-06